Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL612700 Target Snapshot

KATO III stomach cancer cell line · CELL-LINE · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
177Compounds
49Assays
5Approved Drugs
134.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats KATO III stomach cancer cell line as ChEMBL target CHEMBL612700. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
KATO III stomach cancer cell line
CELL-LINE · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL612700
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether KATO III stomach cancer cell line still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameKATO III stomach cancer cell line
Target TypeCELL-LINE
OrganismHomo sapiens
ChEMBL ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelKATO III stomach cancer cell line
UniProt AccessionN/A

KATO III stomach cancer cell line

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as KATO III stomach cancer cell line.

Review nameKATO III stomach cancer cell line
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

5
Approved
1
Phase I
Assay Mix

Activity Type Distribution

IC50134.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3828009 9.15 IC50 0.71 Preclinical
CHEMBL5589978 9.1 IC50 0.79 Preclinical
CHEMBL4297522 8.51 IC50 3.1 Approved
CHEMBL3545376 8.4 IC50 4.0 Approved
CHEMBL5583689 8.38 IC50 4.16 Preclinical
CHEMBL5593563 8.31 IC50 4.93 Preclinical
CHEMBL5590906 8.17 IC50 6.83 Preclinical
CHEMBL5593094 8.14 IC50 7.29 Preclinical
CHEMBL5592678 8.09 IC50 8.08 Preclinical
CHEMBL5591134 7.99 IC50 10.14 Preclinical
Distribution

pChEMBL Value Distribution

13
5.0
17
5.5
9
6.0
8
6.5
7
7.0
12
7.5
6
8.0
1
8.5
2
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

INFIGRATINIB
CHEMBL1852688
Approved 2021
Properties Compare Identifier
PEMIGATINIB
CHEMBL4297522
Approved 2020
Properties Compare Identifier
ERDAFITINIB
CHEMBL3545376
Approved 2019
Properties Compare Identifier
CYTARABINE
CHEMBL803
Approved 1969
Properties Compare Identifier
Assay Landscape

Assay Landscape

51
Total Assays
95
Tested Compounds
1
Assay Types
Functional — 51 assays, 95 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 51 95 6.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine